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SHORT COMMUNICATION 
MORTALITY IN PATIENTS WITH RESPIRATORY AND NON-
RESPIRATORY CARBAPENEM RESISTANT-MULTIDRUG RESISTANT 
ACINETOBACTER INFECTIONS 
Nosheen Nasir, Syed Faisal Mahmood 
Section of Infectious Diseases, Department of Medicine, Aga Khan University Hospital Karachi-Pakistan 
Background: Mortality from carbapenem-multi-drug resistant Acinetobacter infections may vary 
according to site of infection. The objective of this study was to compare mortality in respiratory vs. 
non-respiratory infection with Carbapenem-Multi-drug Resistant Acinetobacter (C-MRAB). Methods: 
We conducted a prospective cohort study to compare mortality rate in patients with respiratory vs. non-
respiratory infection (n=30 each). Results: Results showed that mortality was 40% in the respiratory 
group compared to 23% in non-respiratory group; the difference was not statistically significant 
(p=0.165, RR=1.71, CI=0.73-3.75). There was a significantly higher prior admission rate in patients 
with respiratory infection (p=0.028). Logistic regression did not reveal any modifier effect from other 
variables. Conclusion: This study showed no significant difference in mortality in patients with 
carbapenem-multi-drug resistant acinetobacter respiratory vs. non-respiratory infections. 
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INTRODUCTION 
Acinetobacter baumannii is a gram-negative, aerobic, 
nonfermenting coccobacillus which is often implicated 
in nosocomial infections.1,2 Acinetobacter baumannii 
has been associated with pneumonia, bacteraemia, 
wound infections, urinary tract infections, central line 
associated bacteraemia and meningitis.3,4 Infections 
caused by Acinetobacter sp. are especially difficult to 
treat due to increasing carbapenem resistance and 
surveillance studies have shown that the percentage 
of carbapenem-resistant isolates have gradually 
increased over the last ten years in Europe, North 
America, South Asia and Latin America.5–8  
The associated crude mortality rate with 
carbapenem multidrug resistant Acinetobacter 
baumannii (C-MRAB) is high, ranging from 26–
68%.3,9,10 C-MRAB infections are also associated 
with increased morbidity and a prolonged length of 
hospital and ICU stay.11 While the increased mortality 
may be related directly to limited therapeutic options, 
poor outcomes may also be due to inappropriate 
empirical therapy and the site of infection. Erbay et 
al identified that amongst the sites of infection, 
pneumonia causing bacteraemia was associated with 
the greatest mortality.1 However, as there has been no 
comparison of outcomes with other sites of infection 
we a study to evaluate if respiratory infections with 
C-MRAB were associated with a higher mortality as 
compared to non-respiratory infections with C-
MRAB. 
MATERIAL AND METHODS  
We conducted a prospective observational cohort 
study at a 600, bedded tertiary referral hospital in 
Karachi, Pakistan. All adult patients (age greater than 
18 years) presenting between the 1st of March 2011 
and 31st of August 2011, with a positive culture for C-
MRAB from any site active infection were included. 
Patients with samples sent as an outpatient or those 
with a polymicrobial infection were excluded. 
Patient's medical records were reviewed to obtain 
information regarding age and gender, medical 
diagnoses, co-morbidities, antimicrobial therapy and 
in-hospital mortality, length of hospital stay and 
readmission rate within 1 year of discharge as well as 
biological sample, species of Acinetobacter and 
antibiotic susceptibility.  
Data was entered into SPSS version 16. For 
purpose of the analysis, we assumed that respiratory 
infections were associated with higher risk of 
mortality and were considered as the ‘exposed’ (at 
higher risk) while the non-respiratory group were 
considered ‘non-exposed’. Significance of difference 
of mortality between these two groups was 
determined using Chi square test. Relative risk of 
mortality was calculated for the two groups. 
Influence of confounding variables (gender, source of 
positive culture, diagnoses, comorbid) on mortality 
was determined using logistic regression. A p-value 
of <0.05 was considered statistically significant.  
RESULTS 
A total of 60 patients with Acinetobacter infection were 
included in the study with an equal number in reparatory 
and non-respiratory arms. In the non-respiratory group, 
most patients had a urine tract infection (n=15), 
followed by wound infections (n=7) and vascular 
catheter infections (n=6). Overall, the mean age of our 
patients was 53.7 years ranging between 18–88 years 
(SD±20.0 years). There were 53% males and 47% 
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females. No significant differences in age or gender 
were found amongst patients with respiratory and the 
non-respiratory C-MRAB infections. Among the co-
morbidities, 30% of patients with respiratory infections 
had ischemic heart disease as compared to 6% in non-
respiratory infections (p=0.22). 
The commonest principal diagnosis on 
admission was sepsis, 56% in respiratory and 53% in 
non-respiratory group; followed by trauma 10% in 
respiratory and 16% in non-respiratory group. Out of the 
60 total patients with C-MRAB infection, 19 expired 
whereas 41 were discharged from the hospital (Table-1). 
Although a greater proportion of patients died in the 
respiratory group (40%) compared to non-respiratory 
group (23%), the difference was not statistically 
significant (p=0.165, RR=1.71, CI=0.73–3.75, Figure-
1). There was a significantly higher prior admission rate 
in patients with respiratory infection as compared to 
non-respiratory group (p=0.028).  
The mean length of stay was 18 days for the 
respiratory group and 19 days for non-respiratory group, 
and there was a 23% readmission rate among survivors 
(20% in respiratory group and 26% in non-respiratory 
group). To look for possible bias due to confounding 
variables, logistic regression was performed for 
outcome (discharged vs. died) in relation to categorical 
variables, i.e., group (respiratory vs. non-respiratory), 
gender, comorbid, diagnosis and nosocomial vs. 
community acquired infection. No statistically 
significant effect was observed. 
Appropriate definitive antibiotic therapy with 
intravenous polymyxin B was instituted in 70% of 
patients in respiratory group and 53% in the non-
respiratory group (p=0.388). However, no statistically 
significant difference was observed in terms of 
mortality in both groups who received polymyxin B 
containing regimen versus those who did not receive 
Polymyxin B (p=0.09). 
 
Figure-1: Comparison of outcome between 
respiratory and non-respiratory groups 
Table-1: Patient characteristics in both groups 
Patient Characteristics 
Respiratory 
group 
(n=30) 
Non-
Respiratory 
group (n=30) 
p-value 
Gender   0.30 
Male 18 14  
Female 12 16  
Primary Diagnosis   0.11 
Tumour 2 4  
Pneumonia 5 0  
Sepsis 12 16  
Trauma 3 5  
Autoimmune 2 0  
Other 6 5  
Definitive anti-
microbial therapy 
  0.388 
Polymyxin 21 16  
Carbapenems 4 7  
Source of infection    
Tracheal 28 0  
Urine 0 15  
Sputum 2 0  
Wound 0 7  
Vascular catheter 0 6  
Other 0 2  
Outcome   0.165 
Died 12 7  
Discharged 18 23  
DISCUSSION 
Nosocomial infections with Acinetobacter are an 
emerging cause of morbidity and mortality in 
intensive care units worldwide. We compared the 
differences in outcomes between patients who had 
respiratory infection with C-MRAB and those with 
infection at other sites. We were not able to find a 
statistically significant difference in outcome in both 
groups although there was a trend towards greater 
mortality in patients with C-MRAB pneumonia. This 
is in contrast to studies from Europe12,13 and South 
East Asia14 which have shown increased mortality 
with respiratory infections. For example, Chen et al 
reported a mortality of 39% with C-MRAB 
respiratory tract infections compared to 3.8% with 
vascular catheter or urine catheter related infections 
(p=0.001)15, while Erbay et al1 found that the 
mortality with C-MRAB bacteraemia was 
significantly higher when associated with a 
respiratory infection 78% (p=0.009). Similarly, a 
study from India.16 reported mortality rates of 50% in 
patients with C-MRAB ventilator associated 
pneumonia. However, none of these studies were 
specifically designed or powered to evaluate 
differences in outcomes of different C-MRAB 
infection sites. As a result, most patients with C-
MRAB had a respiratory tract infection (which is the 
most common site), which may lead to the apparent 
increase in mortality. In our study, we attempted to 
control for this by enrolling an equal number of 
patients with respiratory and non-respiratory C-
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MRAB infections. Moreover, most of these studies 
did not distinguish between C-MRAB infection and 
colonization. As a number of risk factors for 
colonization with C-MRAB (such as a high APACHE 
II score and ICU stay)9,17 are associated with 
increased mortality, we attempted to control for this 
by not including patients who were colonized and 
only evaluating actively infected patients. While our 
study was limited by a small sample size and a 
heterogeneous comparator group, we did not find any 
difference in outcomes between respiratory and non-
respiratory C-MRAB infections. Moreover, our study 
was a single centre study so the findings may not be 
generalizable to other settings. 
CONCLUSION 
In conclusion, our study highlighted that while 
mortality with C-MRAB infections is high, this is not 
related to the site of infection and may linked to the 
virulence of the organism or the lack of therapeutic 
options.  
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